Epitome Therapeutics Launches with €4 Million in Total Funding Following Oversubscribed Pre-Seed Round

Epitome Therapeutics, a biotechnology company advancing precision epigenome editing for programmable gene expression, today announced its launch with a total funding of €4 million, comprising an oversubscribed €2 million pre-seed round and €2 million in non-dilutive grant funding.

The pre-seed round was co-led by XISTA Science Ventures and Caesar Ventures, with further participation from Navec Venture Holding GmbH. Additional funding was secured through competitive grants, including support from the Austrian federal development and financing bank AWS and the Austrian Research Promotion Agency (FFG).

Read the full press release here